Cellectar Biosciences Files 8-K for 'Other Event,' Signals Potential Corporate Action

TL;DR

**CLRB filed an 8-K for an 'Other Event' on Feb 2, 2024, hinting at a major corporate move.**

AI Summary

Cellectar Biosciences, Inc. filed an 8-K on February 2, 2024, to report an "Other Event." This filing indicates that the company is using a "Written communications pursuant to Rule 425 under the Securities Act" and "Soliciting material pursuant to Rule 14a-12 under the Exchange Act," which typically relate to corporate actions like mergers, acquisitions, or significant offerings. For investors, this matters because such communications often precede or accompany events that can significantly impact share price, either positively or negatively, depending on the nature of the underlying transaction.

Why It Matters

This filing signals that Cellectar Biosciences is likely engaged in a significant corporate event, such as a merger, acquisition, or a new stock offering, which could materially affect the company's valuation and future prospects.

Risk Assessment

Risk Level: medium — The 'Other Event' designation, combined with the use of specific communication rules, suggests an upcoming corporate action whose details are not yet public, introducing uncertainty and potential volatility.

Analyst Insight

A smart investor would monitor Cellectar Biosciences (CLRB) closely for follow-up announcements, as the 'Other Event' and specific communication rules suggest a material corporate action is imminent. Reviewing the nature of the event (e.g., dilutive offering vs. strategic partnership) will be crucial for assessing impact.

Key Players & Entities

• Cellectar Biosciences, Inc. (company) — the registrant filing the 8-K
• February 2, 2024 (date) — date of earliest event reported
• Rule 425 (other) — Securities Act rule for written communications
• Rule 14a-12 (other) — Exchange Act rule for soliciting material
• CLRB (company) — trading symbol for Cellectar Biosciences, Inc.
• The Nasdaq Capital Market (other) — exchange where CLRB common stock is registered

Forward-Looking Statements

• Cellectar Biosciences will announce details of a significant corporate transaction, such as a merger, acquisition, or a new equity offering. (Cellectar Biosciences, Inc.) — medium confidence, target: 2024-03-01

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share CLRB The Nasdaq Capital M

Filing Documents

• tm244672d1_8k.htm (8-K) — 23KB
• 0001104659-24-009664.txt ( ) — 190KB
• clrb-20240202.xsd (EX-101.SCH) — 3KB
• clrb-20240202_lab.xml (EX-101.LAB) — 33KB
• clrb-20240202_pre.xml (EX-101.PRE) — 22KB
• tm244672d1_8k_htm.xml (XML) — 3KB

01

Item 8.01. Other Events. As a result of the recently announced exercise of Tranche A warrants and other warrant exercises since November 2023, as of January 31, 2024, Cellectar Biosciences, Inc. (the "Company") had 30,452,042 shares of common stock, 319.76 shares of Series E-2 Preferred Stock, and 918.00 shares of Series E-3 Preferred Stock issued and outstanding. In addition, as of January 31, 2024, the Company also had 111 shares of Series D Preferred Stock issued and outstanding.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELLECTAR BIOSCIENCES, INC. Date: February 2, 2024 By: /s/ Chad J. Kolean Name: Chad J. Kolean Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR